FDA Accepts Karyopharm Myelofibrosis Application With 2027 Date
The FDA has accepted Karyopharm's supplemental application for XPOVIO (selinexor) plus ruxolitinib in myelofibrosis, the company announced on November 17, 2026. The agency set a target action date of June 28, 2027, and the filing rests mainly on the Phase 3 SENTRY trial in 353 patients.
Edited and fact-checked by Stephen Sprague
Acceptance starts the review. It does not approve the combination, and the agency can still ask for more data before June 28, 2027.
Richard Paulson got the answer his team had waited for on Tuesday in Newton, Massachusetts.
Karyopharm Therapeutics said the Food and Drug Administration accepted its supplemental New Drug Application for XPOVIO, called selinexor, combined with ruxolitinib for patients with myelofibrosis. The agency set a Prescription Drug User Fee Act target action date of June 28, 2027. Acceptance means the filing is complete enough for a full review. It is not an approval.
Myelofibrosis is a rare blood cancer that scars the bone marrow and enlarges the spleen. The company cites Clarivate data from 2023 for a patient count of about 20,000 people in the United States and 19,000 in the European Union. Fatigue, anemia, night sweats, bone pain and early fullness at meals are common symptoms, and they build over years.
The filing rests mainly on the Phase 3 SENTRY trial, called XPORT-MF-034 and registered as NCT04562389. The trial enrolled 353 patients who had not taken a JAK inhibitor before and who had platelet counts above 100 x 109 per liter. Patients were randomized two to one. The selinexor arm took 60 milligrams once a week plus ruxolitinib, and the control arm took a placebo plus ruxolitinib.
SENTRY had two co-primary endpoints. One measured spleen volume reduction of at least 35 percent at week 24. The other measured the average change in absolute total symptom score over 24 weeks against baseline. Karyopharm presented the results at the 2026 American Society of Clinical Oncology meeting, and the Journal of Clinical Oncology published them at the same time. A later presentation at the European Hematology Association Congress was named one of the six best abstracts at that meeting.
The evidence boundary matters here. JAK inhibitors are the only approved class of therapy for this disease, and ruxolitinib is one of them. Selinexor works through a different mechanism. It blocks exportin 1, a nuclear export protein. If the FDA approves the filing, selinexor plus ruxolitinib would be the first approved combination therapy for myelofibrosis, according to the company. That claim depends on the review, not on the acceptance letter.
Karyopharm already sells XPOVIO in the United States for multiple myeloma, in combinations that include bortezomib and dexamethasone. Chief Medical Officer Reshma Rangwala said patients still face a significant unmet need. Paulson said his teams are preparing for a potential launch during the review. The company disclosed on November 2 that it had entered a restructuring agreement and filed Chapter 11 cases in Texas, and it expects that transaction to close in the first quarter of 2027.
The conversation.
Loading comments…
A little more perspective.
Reading is free. Verified members can comment and reply for $2 a month.